West of Scotland Coronary Prevention Study

Last updated
West of Scotland Coronary Prevention Study
Study typerandomized controlled trial
Datesenrollment February 1989 through September 1991 with 4.9 years follow-up
LocationsWest of Scotland, Glasgow
Published1995
ArticleShepherd, James; et al. (16 November 1995). "Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia". New England Journal of Medicine. 333 (20): 1301–1308. doi:10.1056/NEJM199511163332001.

The West of Scotland Coronary Prevention Study (also known as WOSCOPS) was a landmark [1] randomized controlled trial, published in 1995, that investigated the effects of pravastatin, a cholesterol-lowering drug, on primary prevention of coronary heart disease (CHD) in men with hypercholesterolemia. Conducted in the early 1990s, this study provided critical evidence on the benefits of statins in reducing cardiovascular events in individuals without a history of CHD. It concluded that statin treatment reduced CHD events by 31% after nearly five years of treatment. [2]

Contents

Background

Cardiovascular disease, particularly CHD, is a leading cause of death globally. High low-density lipoprotein (LDL) cholesterol levels are a well-established risk factor for developing CHD. While previous studies [3] [4] [5] had demonstrated the benefits of lipid-lowering agents in patients with existing CHD, the WOSCOPS was one of the first large-scale trials to evaluate the efficacy of statins for primary prevention in individuals without a prior history of cardiovascular events. [2]

Study design

WOSCOPS was a multicenter, randomized, double-blind, placebo-controlled trial conducted in Scotland. The study enrolled 6,595 men aged 45 to 64 years (average 55 years) with elevated total cholesterol levels (average 272 mg/dl) and LDL cholesterol levels (average 192 mg/dL) and no previous history of myocardial infarction. The enrollment period was from February 1989 through September 1991. Participants were randomly assigned to receive either pravastatin (40 mg daily) or a placebo. The primary endpoint was the incidence of nonfatal myocardial infarction and death from CHD. Secondary endpoints included all-cause mortality, coronary revascularization procedures, and stroke. The patients were followed an average of 4.9 years after enrollment. Patient medical records and the national death registry were used to determine clinical results. [2] [6]

Key findings

The results of the WOSCOPS, published in 1995, [2] demonstrated several significant benefits of pravastatin therapy for the primary prevention of CHD:

Clinical implications

The findings of the WOSCOPS had substantial implications for the prevention of CHD. This trial added to the evidence that the incidence of CHD can be reduced with statin therapy. [7] Long-term follow-up demonstrated a sustained reduction in death and coronary events. [8]

Long-term impact

The WOSCOPS was a pivotal trial that contributed to the broader acceptance and use of statins in the primary prevention of cardiovascular disease. Its findings have been corroborated by subsequent studies and meta-analyses, reinforcing the role of statins in reducing the risk of CHD in various populations. [9]

See also

Related Research Articles

<span class="mw-page-title-main">Coronary artery disease</span> Reduction of blood flow to the heart

Coronary artery disease (CAD), also called coronary heart disease (CHD), or ischemic heart disease (IHD), is a type of heart disease involving the reduction of blood flow to the cardiac muscle due to a build-up of atheromatous plaque in the arteries of the heart. It is the most common of the cardiovascular diseases. CAD can cause stable angina, unstable angina, myocardial ischemia, and myocardial infarction.

<span class="mw-page-title-main">Statin</span> Class of drugs to lower cholesterol

Statins are a class of medications that lower cholesterol. They are prescribed typically to people who are at high risk of cardiovascular disease.

<span class="mw-page-title-main">Scandinavian Simvastatin Survival Study</span>

The Scandinavian Simvastatin Survival Study, was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina. The study was sponsored by the pharmaceutical company Merck and enrolled 4,444 people from 94 centres in Scandinavia.

<span class="mw-page-title-main">Hypercholesterolemia</span> High levels of cholesterol in the blood

Hypercholesterolemia, also called high cholesterol, is the presence of high levels of cholesterol in the blood. It is a form of hyperlipidemia, hyperlipoproteinemia, and dyslipidemia.

Dyslipidemia is a metabolic disorder characterized by abnormally high or low amounts of any or all lipids or lipoproteins in the blood. Dyslipidemia is a risk factor for the development of atherosclerotic cardiovascular diseases, which include coronary artery disease, cerebrovascular disease, and peripheral artery disease. Although dyslipidemia is a risk factor for cardiovascular disease, abnormal levels do not mean that lipid lowering agents need to be started. Other factors, such as comorbid conditions and lifestyle in addition to dyslipidemia, is considered in a cardiovascular risk assessment. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged elevation of insulin resistance can also lead to dyslipidemia.

<span class="mw-page-title-main">Atorvastatin</span> Cholesterol-lowering medication

Atorvastatin is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. For the prevention of cardiovascular disease, statins are a first-line treatment. It is taken by mouth.

<span class="mw-page-title-main">Fluvastatin</span> Chemical compound

Fluvastatin is a member of the statin drug class, used to treat hypercholesterolemia and to prevent cardiovascular disease.

<span class="mw-page-title-main">Ezetimibe</span> Medication used to treat high cholesterol

Ezetimibe, sold under the brand name Zetia among others, is a medication used to treat high blood cholesterol and certain other lipid abnormalities. Generally it is used together with dietary changes and a statin. Alone, it is less preferred than a statin. It is taken by mouth. It is also available in the fixed-dose combinations ezetimibe/simvastatin, ezetimibe/atorvastatin, ezetimibe/rosuvastatin, and ezetimibe/bempedoic acid.

<span class="mw-page-title-main">Paul Ridker</span> American epidemiologist and academic

Paul M. Ridker is a cardiovascular epidemiologist and biomedical researcher. He is currently the Eugene Braunwald Professor of Medicine at Harvard University and Brigham and Women's Hospital, where he directs the Center for Cardiovascular Disease Prevention. Ridker also holds an appointment as Professor in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health.

<span class="mw-page-title-main">Bivalirudin</span> Anticoagulant drug

Bivalirudin, sold under the brand names Angiomax and Angiox, among others, is a specific and reversible direct thrombin inhibitor (DTI). Chemically, it is a synthetic congener of the naturally occurring drug hirudin, found in the saliva of the medicinal leech Hirudo medicinalis. It is manufactured by The Medicines Company.

<span class="mw-page-title-main">Vorapaxar</span> Chemical compound

Vorapaxar is a thrombin receptor antagonist based on the natural product himbacine, discovered by Schering-Plough and developed by Merck & Co.

<span class="mw-page-title-main">Myocardial infarction</span> Interruption of cardiac blood supply

A myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow decreases or stops in one of the coronary arteries of the heart, causing infarction to the heart muscle. The most common symptom is retrosternal chest pain or discomfort that classically radiates to the left shoulder, arm, or jaw. The pain may occasionally feel like heartburn. This is the dangerous type of Acute coronary syndrome.

<span class="mw-page-title-main">Dalcetrapib</span> Chemical compound

DalCor is currently conducting the Dal-GenE-2 confirmatory trial with dalcetrapib and placebo in North America under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA).

The JUPITER trial was a clinical trial aimed at evaluating whether statins reduce heart attacks and strokes in people with normal cholesterol levels.

Polycap is a specific five-in-one fixed dose combination polypill created by Cadila Pharmaceuticals Limited of Ahmedabad, India that combines moderate levels of five different medications in a single, one-a-day pill aimed at reducing/preventing heart attacks and strokes.

The AURORA trial was a randomized, double-blind, placebo-controlled study investigating the use of rosuvastatin in the prevention of cardiovascular disease among patients undergoing chronic hemodialysis.

Inclisiran, sold under the brand name Leqvio, is a medication used for the treatment of high low-density lipoprotein (LDL) cholesterol and for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA (siRNA) that acts as an inhibitor of a proprotein convertase, specifically, inhibiting translation of the protein PCSK9.

The Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 trial, also known as PROVE-IT TIMI 22, was a randomized, double-blind, clinical trial that recruited 4,162 people admitted within 10 days of an acute coronary event and randomised them to the lipid-lowering drugs pravastatin (40 mg) or atorvastatin (80 mg) and a 10-day course of the antibiotic gatifloxacin or placebo. The participants enrolled at 349 sites across Australia, Europe, and North America between November 2000 and December 2001, and the study concluded that statin treatment for secondary prevention reduced coronary heart disease (CHD) events and that atorvastatin had a more marked effect than pravastatin. The study was published in The New England Journal of Medicine and reported at the American College of Cardiology Annual Scientific Session in 2004.

Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes was a randomized control trial designed to assess the efficacy of niacin (extended-release) added to statin therapy in reducing cardiovascular events in patients with established atherosclerotic cardiovascular disease (ASCVD). These patients had well-controlled low-density lipoprotein (LDL) cholesterol but persistently low high-density lipoprotein (HDL) cholesterol and elevated triglycerides. 3,414 patients with established ASCVD were enrolled. The mean follow-up period was three years. The trial was stopped early due to a lack of efficacy and a trend towards an increase in the incidence of ischemic stroke.

References

  1. ↑ Myat, Aung; Gershlick, Anthony H., eds. (2012). Landmark Papers in Cardiovascular Medicine. Oxford University Press. p. 32. ISBN   978-0-19-959476-4.
  2. 1 2 3 4 Shepherd, James; Cobbe, Stuart M.; Ford, Ian; et al. (16 November 1995). "Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia". New England Journal of Medicine. 333 (20): 1301–1308. doi:10.1056/NEJM199511163332001.
  3. ↑ Heady, J.A. (May 1981). "A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate: Some statistical aspects". Controlled Clinical Trials. 1 (4): 383–392. doi:10.1016/0197-2456(81)90043-X.
  4. ↑ Rifkind, Basil M. (August 1984). "Lipid research clinics coronary primary prevention trial: Results and implications". The American Journal of Cardiology. 54 (5): 30–34. doi:10.1016/0002-9149(84)90854-3.
  5. ↑ Frick, M. Heikki; Elo, Olli; Haapa, Kauko; et al. (12 November 1987). "Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia". New England Journal of Medicine. 317 (20): 1237–1245. doi:10.1056/NEJM198711123172001.
  6. ↑ "A coronary primary prevention study of Scottish men aged 45-64 years: Trial design". Journal of Clinical Epidemiology. 45 (8): 849–860. August 1992. doi:10.1016/0895-4356(92)90068-x.
  7. ↑ "West of Scotland coronary prevention study: implications for clinical practice". European Heart Journal. 17 (2): 163–164. 2 February 1996. doi:10.1093/oxfordjournals.eurheartj.a014826.
  8. ↑ Ford, Ian; Murray, Heather; Packard, Chris J.; et al. (11 October 2007). "Long-Term Follow-up of the West of Scotland Coronary Prevention Study". New England Journal of Medicine. 357 (15): 1477–1486. doi:10.1056/NEJMoa065994.
  9. ↑ Kashef, Mohammed Amin; Giugliano, Gregory (9 March 2017). "Legacy effect of statins: 20-year follow up of the West of Scotland Coronary Prevention Study (WOSCOPS)". Global Cardiology Science and Practice. 2016 (4). doi:10.21542/gcsp.2016.35.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.